Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

Researchers report that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.